Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$31.62 ▼ -1.33
(-4.05%)
MKT CAP: $342.8M • VOL: 64.3K
52W L $15 52W H $910
ROARABLE / RQD
E • 32/100
PIOTROSKI
1 / 9
IRLA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$58.1M | -$57.3M | -$34.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$84.0M | -$56.8M | -$31.4M |
| EBITDA (Normalized) | -$57.8M | -$57.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$41.4M | -$31.9M | -$18.3M |
| Capital Expenditures (CapEx) | $352.0K | $257.0K | — |
| Free Cash Flow (FCF) | -$41.8M | -$32.2M | -$18.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.8M | $6.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$35.7M | $30.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IRLA.